Exelixis Inc
EXEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.22B
Close$
$171.77
166.2% upside
Current Fair Value
166.2% upsideUndervalued by 166.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.22 Billion |
|---|---|
| Enterprise Value | $16.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.88 |
| Beta | 0.42 |
| Outstanding Shares | 250,808,000 |
Return
| Return on Equity | 33.42% |
|---|---|
| Return on Assets | 24.70% |
| Return on Invested Capital | 35.94% |
Valuation & Multiples
| P/E Ratio | 19.61 |
|---|---|
| PEG | 133.28 |
| Price to Sales | 9.22 |
| Price to Book Ratio | 9.22 |
| Enterprise Value to Revenue | 8.77 |
| Enterprise Value to EBIT | 21.01 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.85
Average shareholder expectationRevenue Estimate
$636.40 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.89
Average shareholder expectationRevenue Estimate
$646.51 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 81.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.53%▼ 100.68% |
|---|---|
| Total Invested | $522.26M▼ 96.33% |
| Investors Holding | 162▼ 617.00% |
ESG Score
No data
About Exelixis Inc
1,077 employees
CEO: Michael Morrissey Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company m...